Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: GlobeNewswire
Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success in its global launch of AXPAXLI™ (also known as OTX-TKI), in development for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), if approved. “We are delighted to welcome David to Ocular Therapeutix. He is an exceptional leader who will play an invalua
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- 3 Reasons OCUL is Risky and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- Is It Too Late To Consider Ocular Therapeutix (OCUL) After Recent Share Price Volatility? [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales [Yahoo! Finance]Yahoo! Finance
- BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD [Yahoo! Finance]Yahoo! Finance
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 1/26/26 - Form 4
- 1/26/26 - Form 3
- 1/23/26 - Form 8-K
- OCUL's page on the SEC website